Popular on PrZen
- Stan Fitzgerald: A Profile in Resilience and Leadership with VFAF Veterans for America First Organizational Support for a Presidential Pardon - 342
- OmegaBrand Introduces New Thermal Transfer Ribbons for Honeywell PC45t Printers - 133
- OneSolution® Dental Implant Centers Introduces Lifetime Warranty on Zirconia Hybrid Teeth - 132
- Cyntexa Joins the ServiceNow Consulting and Implementation Partner Program to Envision, Build, and Deploy Meaningful Experiences - 127
- Texas Center For Oral Surgery & Dental Implants Launches Redesigned Website to Enhance Patient Experience - 117
- High-Performance Pall Ring Fillers for Industrial Columns - 108
- Cyrus Webb and Conversations Media Group Providing New Opportunities for Authors and Creatives to Shine and Thrive - 106
- Nola Blue Records signs legendary Maria Muldaur and estimable Candice Ivory - 106
- Live Good: A Journey of Courage, Education and Purpose - 105
- TikTok Short Videos and Live Streaming E-Commerce Revolutionize the Shopping Experience - 101
Similar on PrZen
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- New Middle East Partnership for up to $40 Million Supporting Entry Into Emerging Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- Matthew Cossolotto's The Joy of Public Speaking – Helping Readers Move from Stage Fright to Stage Delight – Wins 2024 Maincrest Media Book Award
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- COLORICH PACKAGING Will Participate in the COSME Week 2025 TOKYO and Cosmoprof Worldwide Bologna 2025 Exhibition
- Momentum Stock Trading: AI-Driven by Tickeron
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
Powerful Leadership Transition to Optimize Highly Promising AI Platform RenovaroCube for Multi-Cancer Early Detection & Monitoring: Stock Symbol: RENB
PrZen/33561062
Supermajority of RENB Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member Slate.
LOS ANGELES - PrZen -- Realignment to Optimize & Commercialize RenovaroCube, Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies.
New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment.
Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
Strategic Restructuring and Leadership Transition
On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.
RENB CEO David Weinstein commented, "The new five-member board is led by the new Chairman, Maurice van Tilburg, former CEO of Euronext Amsterdam and Director at the Netherlands National Growth Fund". Maurice brings a wealth of experience in Corporate Governance, operations, and product development critical to executing on RenoVision 2.0. Moreover, he is based in Amsterdam to assist our AI driven early cancer detection program at RenovaroCube."
Mr. Weinstein continued, "The rest of our experienced Board of Directors includes: James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International.Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus.Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics."
RENB Revitalized Commitment to "Ambitious Innovation" Includes:
1) Strategic Asset Review & Pipeline Prioritization.
2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).
3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.
4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.
5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
On September 19th RENB announced thart PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
Advancing AI models by leveraging the latest state-of-the-art techniques.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
Disclaimer and Disclosure: www.aibrandnetwork.com
New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment.
Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
Strategic Restructuring and Leadership Transition
On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.
RENB CEO David Weinstein commented, "The new five-member board is led by the new Chairman, Maurice van Tilburg, former CEO of Euronext Amsterdam and Director at the Netherlands National Growth Fund". Maurice brings a wealth of experience in Corporate Governance, operations, and product development critical to executing on RenoVision 2.0. Moreover, he is based in Amsterdam to assist our AI driven early cancer detection program at RenovaroCube."
Mr. Weinstein continued, "The rest of our experienced Board of Directors includes: James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International.Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus.Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics."
RENB Revitalized Commitment to "Ambitious Innovation" Includes:
1) Strategic Asset Review & Pipeline Prioritization.
2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).
3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.
4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.
5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
On September 19th RENB announced thart PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
Advancing AI models by leveraging the latest state-of-the-art techniques.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
Disclaimer and Disclosure: www.aibrandnetwork.com
Source: Corporate Ads
0 Comments
Latest on PrZen
- The One Experience™, Inc. Announces Inspiring Lineup of Pathway Guides for The One 2025 Event
- Stange Law Firm Opens Divorce and Family Law Office in Louisville, Kentucky
- Stange Law Firm Expands to Houston, Bringing Family Law Services to Texas
- A Look Back at Our 2024 Accomplishments: Complete Sliding Doors & Windows Continues to Lead with Excellence
- Franchising Success, One Pour at a Time
- FamBam Foods® Expands Healthy Snack Portfolio with Launch of Caulitos®
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- "Global Accreditation Failures: How the Wuhan Lab Certification Exposed Systemic Weaknesses and Paved the Way for COVID-19"
- Get to know Dr. Raphael E. Cuomo, PhD, Professor and Scientist at the University of California, San Diego
- Ohio Medicare (Plan Brian C. Moore), has once again been distinguished as Ohio's Top-Ranked and Number-One-Rated "Best Choice" Medicare Expert!
- Manchester Insurance Announces Best Rates in Florida for Home Insurance
- New Middle East Partnership for up to $40 Million Supporting Entry Into Emerging Global MOBA Digital Game Arena: NIP Group (Stock Symbol: NIPG)
- King Dumpsters Canton Launches Affordable, Reliable Dumpster Rental Services in Canton, Ohio
- Matthew Cossolotto's The Joy of Public Speaking – Helping Readers Move from Stage Fright to Stage Delight – Wins 2024 Maincrest Media Book Award
- Lady Bird Laser Spa: Empowering Beauty with Advanced Skin Treatments and Exceptional Service
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- A Historic Night Awaits: RNHA Celebrating the Power of the Latino Vote at Inauguration 2025
- Namebadges.com Expands Shipping Services to Mexico and Canada
- Keells Leverages Cyntexa and Salesforce to Redefine Customer Loyalty with Digital Innovation
- PhaseZero Releases CxCommerce™ 7.0 with Proven Scale for the Largest Enterprises and Affordability for Small Businesses